Abbott Laboratories (ABT)
Health Care3 articles
Market Mood
Abbott Labs (ABT) stock price target cut to $120 by Benchmark
Benchmark has reduced its price target for Abbott Labs (ABT) stock to $120. This change reflects a re-evaluation of the company's valuation metrics. Such a downgrade can influence market perceptions and potentially impact stock performance. It is essential to monitor how this adjustment affects trading volume and investor sentiment moving forward.
Read More
Abbott (ABT) Faces 20% Drop Amid Earnings Concerns and Lawsuit
Abbott Laboratories (ABT) has seen its stock decline 20% this year, influenced by a recent earnings report and ongoing legal issues concerning its special baby formula. Jim Cramer highlighted that Abbott recently acquired Exact Sciences for approximately $21 billion, a deal representing a 51% premium over its prior trading price, marking the largest healthcare merger in two years. Despite this acquisition, Abbott's stock has fallen more than $6 in two days following the announcement. Investors are cautious and awaiting additional insights during the upcoming earnings call to assess future growth potential.
Read More
Abbott (ABT) Jury Orders $53 Million Payment in Formula Case
A jury has ordered Abbott (ABT) to pay $53 million following a trial related to preterm infant formula. This ruling could have significant implications for Abbott's financial position and market perception, especially in terms of product liability risks. The outcome of the trial may influence future litigation and customer trust in the company's products. Market analysts may watch for potential impacts on Abbott's stock price and overall valuation as a result.
Read More